Search
EHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy
Dates: November 23-25, 2017
Location: Amsterdam, The Netherlands
Chair: WE Fibbe, F Dazzi
Organized by:
EHA and the EHA Scientific Working Group on Mesenchymal Stromal Cells
The SWG Meeting “Shaping the future of MSC therapy” brought together basic science, as well as translational and clinical research.…
EHA24 is YOUR congress – here’s how you can make the most of it
Congress season is an exciting time for any field. It’s a time when experts come together to share the latest developments, and also an opportunity to see friends and colleagues who you haven’t seen in a while.
Read moreEHA-SWG Scientific Meeting on Challenges in the Diagnosis and Management of Myeloproliferative Neoplasms
Dates: October 12-14, 2017
Location: Budapest, Hungary
Chairs: C Harrison, JJ Kiladjian
EHA and the EHA Scientific Working Group on Myeloproliferative Neoplasms are organizing this EHA-SWG Scientific Meeting on Challenges in the Diagnosis and Management of Myeloproliferative Neoplasms.
First Horizon 2020 Work Programme update – budget, and launch of FTI and innovation prizes
Click here for the PDF.
Read moreCall for research proposals within the Scientific Excellence Work Package of the GoCART Coalition
Dear GoCART community,
With more than 5,000 CAR-T infusions registered in the EBMT Registry, EBMT and EHA are proud to announce the third call for research proposals within the Scientific Excellence Work Package of the GoCART Coalition.
EHA-SWG Scientific Meeting on MDS/MPN/AML: Commonalities and Differences of Myeloid Neoplasms
Join us for this unique and rare opportunity and exchange ideas with MDS, MPN, and AML experts in one meeting. Internationally renowned experts will provide presentations and share the recent developments and answers to your clinical questions.
Read moreHematopoietic stem cells: New results to be presented at the 18th Congress of the EHA
During ageing, this fine-tuned regulatory network may become altered, leading to abnormal HSC regulation. The functional quality of HSCs decreases with age partly due to an accumulation of damaged DNA, leading to an increased incidence of hematological malignancies.
Read moreEHA supports the European Medicines Agency's investigation into risk based quality management of clinical trials
EHA has responded to the EMA’s call for comments on the reflection paper on February 15.
Read moreThe interaction of von Willebrand factor with platelet glycoprotein Ib: pathological implications and clinical manifestations
The EHA Specialized Working Group (SWG) on Thrombocytopenias and Platelet Function Disorders and the EHA-SWG on Bleeding and Thrombosis are pleased to collaborate on a recent free webinar: "The interaction of von Willebrand factor with platelet glycoprotein Ib: pathological implications and clinical…
Read moreReport on first EHA-SWG Scientific Meeting
The meeting was organized with the main support of the EHA in collaboration with the Hematology Unit of G. Gaslini Children’s Hospital and was sponsored by Novartis and Alexion.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- »